Trial Profile
Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2013
Price :
$35
*
At a glance
- Drugs Ganciclovir (Primary)
- Indications Keratoconjunctivitis
- Focus Therapeutic Use
- Sponsors Laboratoires Thea
- 28 Apr 2012 Additional trial location (Germany) identified as reported by European Clinical Trials Database.
- 28 Apr 2012 Planned number of patients changed to 80 as reported by European Clinical Trials Database.
- 28 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-002455-16).